Clinical Trial Update: Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on intrathecal transplantation of umbilical cord-derived mesenchymal stem cells for sub-acute spinal cord injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• UC-MSC (umbilical cord-derived mesenchymal stem cells)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Spinal Cord Injury | Phase 2 | Status: UNKNOWN